Baltimore-based Insilico Medicine landed a new strategic investment from Chinese biotech company WuXi AppTec.
The amount of the funding was not disclosed, but the investment also includes a strategic partnership between Insilico and WuXi, which specializes in contract research for the pharmaceutical and medical device industries.